199 related articles for article (PubMed ID: 26222090)
1. α7 nicotinic ACh receptor-deficient mice exhibit sustained attention impairments that are reversed by β2 nicotinic ACh receptor activation.
Kolisnyk B; Al-Onaizi MA; Prado VF; Prado MA
Br J Pharmacol; 2015 Oct; 172(20):4919-31. PubMed ID: 26222090
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of nicotinic α7 and α4/β2 sub-receptor agonists for enhancing learning and attentional filtering in nonhuman primates.
Azimi M; Oemisch M; Womelsdorf T
Psychopharmacology (Berl); 2020 Apr; 237(4):997-1010. PubMed ID: 31865424
[TBL] [Abstract][Full Text] [Related]
3. Subtype-selective nicotinic acetylcholine receptor agonists can improve cognitive flexibility in an attentional set shifting task.
Wood C; Kohli S; Malcolm E; Allison C; Shoaib M
Neuropharmacology; 2016 Jun; 105():106-113. PubMed ID: 26772970
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.
Young JW; Meves JM; Geyer MA
Behav Brain Res; 2013 Mar; 240():119-33. PubMed ID: 23201359
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
Mori Y; Mouri A; Kunisawa K; Hirakawa M; Kubota H; Kosuge A; Niijima M; Hasegawa M; Kurahashi H; Murakami R; Hoshi M; Nakano T; Fujigaki S; Fujigaki H; Yamamoto Y; Nabeshima T; Saito K
Behav Brain Res; 2021 May; 405():113191. PubMed ID: 33607168
[TBL] [Abstract][Full Text] [Related]
6. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task.
Hoyle E; Genn RF; Fernandes C; Stolerman IP
Psychopharmacology (Berl); 2006 Dec; 189(2):211-23. PubMed ID: 17019565
[TBL] [Abstract][Full Text] [Related]
7. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor.
Young JW; Finlayson K; Spratt C; Marston HM; Crawford N; Kelly JS; Sharkey J
Neuropsychopharmacology; 2004 May; 29(5):891-900. PubMed ID: 14970827
[TBL] [Abstract][Full Text] [Related]
8. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
Wallace TL; Callahan PM; Tehim A; Bertrand D; Tombaugh G; Wang S; Xie W; Rowe WB; Ong V; Graham E; Terry AV; Rodefer JS; Herbert B; Murray M; Porter R; Santarelli L; Lowe DA
J Pharmacol Exp Ther; 2011 Jan; 336(1):242-53. PubMed ID: 20959364
[TBL] [Abstract][Full Text] [Related]
9. α7 Nicotinic Acetylcholine Receptor Relieves Angiotensin II-Induced Senescence in Vascular Smooth Muscle Cells by Raising Nicotinamide Adenine Dinucleotide-Dependent SIRT1 Activity.
Li DJ; Huang F; Ni M; Fu H; Zhang LS; Shen FM
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1566-76. PubMed ID: 27339462
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice.
Levin ED; Petro A; Rezvani AH; Pollard N; Christopher NC; Strauss M; Avery J; Nicholson J; Rose JE
Behav Brain Res; 2009 Jan; 196(2):207-13. PubMed ID: 18831991
[TBL] [Abstract][Full Text] [Related]
11. α7 Nicotinic acetylcholine receptor contributes to the alleviation of lung ischemia-reperfusion injury by transient receptor potential vanilloid type 1 stimulation.
Li X; Xu Y; Cheng Y; Wang R
J Surg Res; 2018 Oct; 230():164-174. PubMed ID: 30100034
[TBL] [Abstract][Full Text] [Related]
12. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
13. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
Pieschl RL; Miller R; Jones KM; Post-Munson DJ; Chen P; Newberry K; Benitex Y; Molski T; Morgan D; McDonald IM; Macor JE; Olson RE; Asaka Y; Digavalli S; Easton A; Herrington J; Westphal RS; Lodge NJ; Zaczek R; Bristow LJ; Li YW
Eur J Pharmacol; 2017 Jul; 807():1-11. PubMed ID: 28438647
[TBL] [Abstract][Full Text] [Related]
14. Nicotine withdrawal-induced inattention is absent in alpha7 nAChR knockout mice.
Higa KK; Grim A; Kamenski ME; van Enkhuizen J; Zhou X; Li K; Naviaux JC; Wang L; Naviaux RK; Geyer MA; Markou A; Young JW
Psychopharmacology (Berl); 2017 May; 234(9-10):1573-1586. PubMed ID: 28243714
[TBL] [Abstract][Full Text] [Related]
15. The selective alpha7 nicotinic acetylcholine receptor agonist AR-R17779 does not affect ischemia-reperfusion brain injury in mice.
Hammarlund ME; Darsalia V; Mjörnstedt F; Pattanaik B; Mallard C; Rocha-Ferreira E; Patrone C; Johansson ME
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34008839
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
17. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.
Parikh V; Ji J; Decker MW; Sarter M
J Neurosci; 2010 Mar; 30(9):3518-30. PubMed ID: 20203212
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of cellular prion protein (PrPC) is related with activation of alpha7 nicotinic acetylcholine receptor (α7nAchR)-mediated autophagy flux.
Jeong JK; Park SY
Oncotarget; 2015 Sep; 6(28):24660-74. PubMed ID: 26295309
[TBL] [Abstract][Full Text] [Related]
19. Alpha7 Nicotinic Acetylcholine Receptor Alleviates Inflammatory Bowel Disease Through Induction of AMPK-mTOR-p70S6K-Mediated Autophagy.
Shao BZ; Wang SL; Fang J; Li ZS; Bai Y; Wu K
Inflammation; 2019 Oct; 42(5):1666-1679. PubMed ID: 31236857
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.
Xie H; Yepuri N; Meng Q; Dhawan R; Leech CA; Chepurny OG; Holz GG; Cooney RN
Rev Endocr Metab Disord; 2020 Dec; 21(4):431-447. PubMed ID: 32851581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
